Xilio Therapeutics Files 8-K on Financials
Ticker: XLO · Form: 8-K · Filed: Mar 11, 2025 · CIK: 1840233
Sentiment: neutral
Topics: financial-reporting, sec-filing
TL;DR
Xilio Therapeutics filed an 8-K on March 11, 2025, detailing financial condition and results of operations.
AI Summary
On March 11, 2025, Xilio Therapeutics, Inc. filed an 8-K report. The filing primarily concerns the company's results of operations and financial condition, as well as financial statements and exhibits. No specific financial figures or operational updates were detailed in the provided excerpt.
Why It Matters
This filing indicates that Xilio Therapeutics is providing updates on its financial performance and condition to the SEC, which is important for investors to monitor the company's health.
Risk Assessment
Risk Level: low — The filing is a routine 8-K reporting financial condition and results of operations, with no immediate negative or positive indicators in the provided text.
Key Players & Entities
- Xilio Therapeutics, Inc. (company) — Registrant
- March 11, 2025 (date) — Date of report
- Delaware (jurisdiction) — State of Incorporation
- 001-40925 (identifier) — Commission File Number
- 85-1623397 (identifier) — IRS Employer Identification No.
- 828 Winter Street, Suite 300 Waltham, Massachusetts 02451 (address) — Principal Executive Offices
- (857) 524-2466 (phone_number) — Registrant's telephone number
FAQ
What is the primary purpose of this 8-K filing by Xilio Therapeutics, Inc.?
The primary purpose of this 8-K filing is to report on Xilio Therapeutics, Inc.'s Results of Operations and Financial Condition, as well as to provide Financial Statements and Exhibits.
On what date was this 8-K report filed?
This 8-K report was filed on March 11, 2025.
In which state is Xilio Therapeutics, Inc. incorporated?
Xilio Therapeutics, Inc. is incorporated in Delaware.
What is the principal executive office address for Xilio Therapeutics, Inc.?
The principal executive office address for Xilio Therapeutics, Inc. is 828 Winter Street, Suite 300, Waltham, Massachusetts 02451.
What is the Commission File Number for Xilio Therapeutics, Inc.?
The Commission File Number for Xilio Therapeutics, Inc. is 001-40925.
Filing Details
This Form 8-K (Form 8-K) was filed with the SEC on March 11, 2025 regarding Xilio Therapeutics, Inc. (XLO).